White Paper_ICER and Parallel Modeling

Fill out the form to download the white paper.

When a pharma product goes through an ICER assessment, there is a 97% chance that the manufacturer will face a price cut recommendation. But that doesn't have to be the case when your product undergoes an ICER review...

In this white paper, we discuss how multiple global pharmaceutical companies successfully mitigated ICER reviews, impacting ICER's recommendations. Download the white paper to learn how you can mitigate an impending ICER review with:

  • Independent parallel models
  • Cost-effectiveness and budget impact analyses
  • Evidence and supporting materials
  • and more...